en · de · es · fr · pt
epitalon-notes.peptides9000.com › Info › Epitalon Peptide Background And Structure — 2026 Update

Epitalon Peptide Background And Structure — 2026 Update

By Editorial Desk · published 2026-06-28 · last reviewed 2026-08-01 · Info

If you have been reading about bioregulator and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.

Epitalon Peptide Background and Structure

The four residues give epitalon a molecular formula of C14H22N4O9 and a molecular weight near 390.35 daltons. The presence of two acidic residues, glutamate and aspartate, makes the free peptide strongly acidic, while the alanine and glycine ends provide neutral, nonpolar character. This combination produces a molecule with substantial water solubility. Because there are no cysteine, methionine, or tryptophan residues, the peptide lacks the most common oxidation-sensitive side chains, which simplifies handling compared with many longer peptides.

The proposed relationship between epitalon and pineal function is a central part of its background. Khavinson's group reported that short peptides corresponding to regions of larger pineal proteins could influence gene expression in cells. Epitalon was framed as a synthetic analogue of an active fragment rather than a direct isolation product. Whether the tetrapeptide reproduces the effects of the parent extract is an open question, because comparative studies are limited and the parent extract itself is not a single defined substance.

Interest in epitalon is usually discussed within the broader field of short peptide bioregulators, a category that includes other synthetic di-, tri-, and tetrapeptides studied by the same research group. These compounds share a common rationale: that small fragments of tissue-derived proteins can retain biological activity and can be produced reproducibly. The category as a whole remains outside mainstream pharmacological consensus, and epitalon specifically has a limited presence in independent, non-Russian research literature, which shapes how its evidence base is described.

Analytical Methods and Storage

Identity and purity of epitalon samples are normally established by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, combined with mass spectrometry. The mass spectrum confirms the expected molecular ion and can reveal truncated or oxidised by-products. Amino acid analysis after acid hydrolysis verifies that the four residues are present in the expected ratio. Certificates typically report a purity figure taken from chromatographic peak area, expressed as a percentage of total integrated signal.

Lyophilised epitalon is generally held at minus twenty degrees Celsius in a sealed container kept dry and dark. Cooler conditions are sometimes recommended for long-term archives. The solid takes up moisture readily enough that repeated opening of a vial introduces water, so dividing a batch into smaller portions before storage lowers degradation risk. Aqueous solutions are less durable than the dry powder and are usually prepared shortly before use, then kept cold and shielded from light to slow hydrolysis and oxidation.

Epitalon at a glance

PropertyValueNotes
Amino acid sequenceAla-Glu-Asp-GlyTetrapeptide, often abbreviated AEDG
Molecular formulaC14H22N4O9Free peptide, unmodified termini
Molecular weight~390.35 DaCalculated for the free acid form
AppearanceWhite to off-white powderTypical lyophilized product form
Solubility classFreely soluble in waterTwo acidic residues dominate ionic character

Structure, Naming and Discovery

Epitalon is a synthetic tetrapeptide whose four residues are alanine, glutamate, aspartate and glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9 and its monoisotopic mass is near 390.35 daltons. The peptide carries two acidic side chains, so it is neutral to negatively charged in most aqueous buffers. Published reference summaries usually list it under both spellings, epitalon and epithalon, and treat the two names as the same material.

The compound is generally described as a synthetic analogue of a fragment isolated from a pineal gland extract. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology introduced it during the 1980s and 1990s while studying short peptides from animal tissue. The original extract, called epithalamin, is a heterogeneous mixture, whereas epitalon is a single defined sequence. That distinction matters because findings reported for the extract are not automatically findings about the pure tetrapeptide, and claims about broader biological effects remain a separate question from the chemical identity described here.

Residue composition is the property that most cleanly separates verified material from mislabelled samples. Alanine, glutamate, aspartate and glycine appear in that order from the N-terminus, and the two acidic residues sit in the middle of the chain. Because the peptide is short, it can be produced by solid-phase synthesis and characterised by mass spectrometry without ambiguity. Any reported sample whose measured mass departs substantially from 390 daltons is a different compound or a degraded mixture rather than epitalon.

Related pages on this site

Analytical Verification and Storage

Verification of a sample usually begins with reversed-phase high-performance liquid chromatography, which resolves the peptide from truncated sequences and other impurities and expresses purity as a percentage of total peak area. Mass spectrometry by electrospray ionisation or matrix-assisted laser desorption supplies an independent check, because the measured mass can be compared against the theoretical value for AEDG. Amino acid analysis or tandem mass spectrometry sequencing can confirm residue order. Each of these methods answers a different question: a purity figure does not establish identity, and an identity match does not establish how much of the material is intact peptide.

The molecule is a short, linear, hydrophilic peptide that dissolves readily in water or aqueous buffer. Its principal chemical liabilities are hydrolytic rather than oxidative, since it contains no cysteine, methionine, or tryptophan residues. The aspartate–glycine step is a recognised site for aspartimide formation under mildly acidic or basic conditions, generating isoaspartate and succinimide-related products over time. Desiccated lyophilised powder held at −20 °C is comparatively stable, whereas dilute solutions degrade faster and are best frozen as single-use aliquots rather than thawed repeatedly.

Background and Proposed Mechanism

The most frequently cited proposed action is induction of telomerase, the enzyme that adds repeat sequences to chromosome ends. Cell-culture work from the originating group reported higher telomerase reverse transcriptase expression and measurable telomere elongation in human somatic cells after exposure. How a four-residue peptide would reach nuclear gene regulation is not established, and no cell-surface receptor or uptake route has been identified. Additional reports describe changes in melatonin secretion, antioxidant enzyme activity and lipid peroxidation in aged animals, but these findings remain mechanistically unconnected to the telomerase observation.

Published evidence comes mainly from Russian-language journals and from a single research group, with small sample sizes and limited independent replication. A few laboratories outside that group have examined related peptides and reported weaker or absent telomerase effects, so the central claim is best described as contested rather than settled. Rodent studies report modest changes in some ageing markers and in survival, but designs vary and control conditions are often sparse. No large randomised trial in humans has been published, and long-term safety data in healthy populations are correspondingly thin.

Analytical Characterization and Stability

Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.

Stability of the tetrapeptide follows ordinary peptide chemistry rather than any unusual structural feature. The aspartate-glycine pair is prone to aspartimide formation under mildly basic or neutral conditions, and deamidation can follow, altering both mass and chromatographic retention. Dry lyophilised powder kept at or below minus twenty degrees Celsius is the usual handling recommendation, with repeated freeze-thaw cycles avoided. Once dissolved in neutral aqueous buffer, degradation proceeds over days to weeks depending on pH and temperature, while acidic conditions generally slow the aspartimide route. A formal stability-indicating study has not been published in the indexed literature.

Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.

Notes from published material

=== 11 April === Russia launched a massive air attack on cities and energy infrastructure across Ukraine, killing five people in Mykolaiv and destroying the Trypilska thermal power plant in Ukrainka, Kyiv Oblast. Two storage facilities belonging to the state gas firm Naftogaz were also targeted. President Zelenskyy said that the power plant was destroyed after air defenses ran out of missiles after intercepting seven Russian missiles, resulting in four other missiles hitting the facility. The FSB claimed to have thwarted an attempted landing by Ukrainian special forces in occupied Kherson Oblast, inflicting casualties and capturing a commando. Ukrainian authorities ordered the evacuation of families with children from 47 communities in Kharkiv Oblast near the border with Russia due to Russian attacks. Ukrainian military commanders convinced the Verkhovna Rada to drop a clause from a bill on mobilization of Ukrainian military personnel that allowed soldiers who had fought for 36 months a chance to be discharged. Citing the ongoing Russian offensive, the officers claimed that the clause would "weaken the defence forces". The bill was passed later in the day after over four thousand amendments were submitted since its introduction in February 2024. It must now be signed into law by Zelenskyy.

=== Antibacterial peptide === Pardaxin has a helix-hinge-helix structure. This structure is common in peptides that act selectively on bacterial membranes and cytotoxic peptides that lyse mammalian and bacterial cells. Pardaxin shows a significantly lower hemolytic activity towards human red blood cells compared to melittin. The C-terminal tail of pardaxin is responsible for this non-selective activity against the erythrocytes and bacteria. The amphiphilic C-terminal helix is the ion-channel lining segment of the peptide. The N-terminal α-helix is important for the insertion of the peptide to the lipid bilayer of the cell. The mechanism of pardaxin is dependent on the membrane composition. Pardaxin significantly disrupts lipid bilayers composed of zwitterionic lipids, especially those composed of 1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC). This suggests a carpet mechanism for cell lysis. The carpet mechanism is when a high density of peptides accumulates on the target membrane surface. The phospholipid displacement changes in fluidity, and the cellular contents leak out. The presence of anionic lipids or cholesterol was found to reduce the peptide's ability to disrupt bilayers.

== Pharmacology == Mitragynine pseudoindoxyl is a μ-opioid receptor agonist and δ-opioid receptor antagonist. Animal studies have shown it causes reduced tolerance, withdrawal, and respiratory depression compared to morphine. Respiratory depression is the primary cause of death in the vast numbers of fatalities linked to fentanyl and other opioids. As an atypical analgesic it has a remarkably strong affinity for the MOR (0.087nM), compared with mitragynine at 7.24nM and 7-hydroxymitragynine at 13.5nM (lower figure means stronger binding). This substance has great potential on its own or as a starting point in the development of new and safer opioids. There are currently no documented overdose deaths as a result of usage of the pure substance. However, recreational use of the isolated alkaloid is rare, as it is typically sold for recreational use in a mixture that also contains 7-hydroxymitragynine. This alkaloid may be a biased agonist at the μ-opioid receptor; this may explain the more favorable side effect profile found in some research. However, a 2020 review of these and more recent studies has found issues with some methods originally used to determine ligands to be G protein biased. Oliceridine, thought to be the prototypical G protein biased μ-opioid receptor agonist, along with PZM21 and buprenorphine, were found to be unbiased. Rather, their low intrinsic efficacy interfered with the results of highly amplified assays.

Sources: en.wikipedia.org

Further detail

Examples of potent CYP1A2 inhibitors include ethinylestradiol (found in hormonal birth control), fluoroquinolones (e.g., ciprofloxacin), fluvoxamine, and St. John's wort, while potent CYP1A2 inducers include phenytoin, rifampin, ritonavir, and tobacco. A study found that ritonavir, a strong CYP3A4 and CYP2D6 inhibitor and moderate CYP1A2 inducer, increased trazodone peak levels by 1.4-fold, trazodone area-under-the-curve levels by 2.4-fold, and decreased trazodone clearance by 50%. This was associated with adverse effects such as nausea, hypotension, and syncope. Another study found that the strong CYP3A4 inducer carbamazepine reduced concentrations of trazodone by 60 to 74%. The strong CYP2D6 inhibitor thioridazine has been reported to increase trazodone levels by 1.4-fold and concentrations of mCPP by 1.5-fold. Fluoxetine, a strong inhibitor of CYP2D6 and a weak or moderate inhibitor of CYP3A4, has been reported to increase levels of trazodone by 1.3- to 1.7-fold and of mCPP by 3.0- to 3.4-fold. Conversely, CYP2D6 genotype has not been found to predict trazodone or mCPP concentrations with trazodone therapy, although CYP2D6 genotype did correlate with side effects like dizziness and prolonged corrected QT interval. Smokers have lower levels of trazodone and higher ratios of mCPP to trazodone. Trazodone levels were 30% lower in smokers and mCPP to trazodone ratio was 1.3-fold higher in smokers, whereas mCPP concentrations were not different between smokers and non-smokers. Smoking is known to induce CYP1A2, and this may be involved in these findings.

== Hydrogen bonds in polymers == Hydrogen bonding plays an important role in determining the three-dimensional structures and the properties adopted by many proteins. Compared to the C−C, C−O, and C−N bonds that comprise most polymers, hydrogen bonds are far weaker, perhaps 5% as strong. Thus, hydrogen bonds can be broken by chemical or mechanical means while retaining the basic structure of the polymer backbone. This hierarchy of bond strengths (covalent bonds being stronger than hydrogen-bonds being stronger than van der Waals forces) is relevant in the properties of many materials.

The real chromatographic analysis starts with the introduction of the sample onto the column. The development of capillary gas chromatography resulted in many practical problems with the injection technique. The technique of on-column injection, often used with packed columns, is usually not possible with capillary columns. In the injection system in the capillary gas chromatograph the amount injected should not overload the column and the width of the injected plug should be small compared to the spreading due to the chromatographic process. Failure to comply with this latter requirement will reduce the separation capability of the column. As a general rule, the volume injected, Vinj, and the volume of the detector cell, Vdet, should be about 1/10 of the volume occupied by the portion of sample containing the molecules of interest (analytes) when they exit the column. Some general requirements which a good injection technique should fulfill are that it should be possible to obtain the column's optimum separation efficiency, it should allow accurate and reproducible injections of small amounts of representative samples, it should induce no change in sample composition, it should not exhibit discrimination based on differences in boiling point, polarity, concentration or thermal/catalytic stability, and it should be applicable for trace analysis as well as for undiluted samples. However, there are a number of problems inherent in the use of syringes for injection. Even the best syringes claim an accuracy of only 3%, and in unskilled hands, errors are much larger.

Sources: en.wikipedia.org

Supporting material

Staphylococcus, Streptococcus and diphtheria bacillus (Corynebacterium diphtheriae) were easily killed, but there was no effect on typhoid bacterium (Salmonella typhimurium) and the bacterium once thought to cause influenza (Haemophilus influenzae). He prepared a culture method from which he could obtain the mould juice, which he called "penicillin" on 7 March 1929, "to avoid the repetition of the rather cumbersome phrase 'mould broth filtrate'." In his Nobel lecture of 1945 he gave a further explanation, saying:

== Development roadmap == In Sep 2017, Adobe announced the roadmap anticipating releases in 2018 and 2020. Among the key features anticipated for the 2016 release were a new performance monitor, enhancements to asynchronous programming, revamped REST support, and enhancements to the API Manager, as well as support for CF2016 projected into 2024. As for the 2020 release, the features anticipated at that time (in 2017) were configurability (modularity) of CF application services, revamped scripting and object-oriented support, and further enhancements to the API Manager.

== Discovery == Notch was discovered in a mutant Drosophila in March 1913 in the lab of Thomas Hunt Morgan. This mutant emerged after several generations of crossing out and back-crossing beaded winged flies with wild type flies and was first characterized by John S. Dexter. The most frequently observed phenotype in Notch mutant flies is the appearance of a concave serration at the most distal end of the wings, for which the gene is named, accompanied by the absence of marginal bristles. This mutant was found to be a sex-linked dominant on the X chromosome that could only be observed in heterozygous females as it was lethal in males and homozygous females. The first Notch allele was established in 1917 by Charles William Metz and Calvin Bridges. In the late 1930s, studies of fly embryogenesis done by Donald F. Poulson provided the first indication of Notch's role in development. Notch mutant males exhibited a lack of the inner germ layers, the endoderm and mesoderm, that resulted in failure to undergo later morphogenesis embryonic lethality. Later studies in early Drosophila neurogenesis provided some of the first indications of Notch's roll in cell-cell signaling, as the nervous system in Notch mutants was developed by sacrificing hypodermal cells. Starting in the 1980s researchers began to gain further insights into Notch function through genetic and molecular experiments.

Sources: en.wikipedia.org

Frequently asked questions

What is epitalon made of?

Epitalon is a synthetic tetrapeptide composed of four amino acids: alanine, glutamate, aspartate, and glycine. It is written as Ala-Glu-Asp-Gly. The free peptide has a molecular weight of about 390 daltons and is normally supplied as a lyophilized powder.

Is epitalon extracted from the pineal gland?

No. Epitalon is chemically synthesized, not extracted. It was designed as a short synthetic fragment conceptually related to larger pineal peptides studied in the same research tradition, particularly the extract known as epithalamin. The two are distinct materials with different compositions.

Why is epitalon described as a bioregulator?

The term bioregulator is used in this research tradition for short peptides proposed to influence gene expression or cell function. Epitalon is grouped with other synthetic short peptides under this label. The term reflects a proposed mechanism rather than an established drug classification.

How is epitalon purity measured?

The usual approach is reversed-phase HPLC with ultraviolet detection, reported as a percentage of total peak area. Mass spectrometry is used alongside chromatography to confirm identity rather than purity alone.

Network